Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

BACKGROUND: Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) programs. The objective of this study was to estimate and to compare HCV treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Aas, Christer F., Vold, Jørn Henrik, Skurtveit, Svetlana, Odsbu, Ingvild, Chalabianloo, Fatemeh, Lim, Aaron G., Johansson, Kjell Arne, Fadnes, Lars Thore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325258/
https://www.ncbi.nlm.nih.gov/pubmed/32605625
http://dx.doi.org/10.1186/s13011-020-00286-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325258/
https://www.ncbi.nlm.nih.gov/pubmed/32605625
http://dx.doi.org/10.1186/s13011-020-00286-2

Ejemplares similares